We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfolio
Read MoreHide Full Article
Key Takeaways
Stryker launched Mako RPS, a handheld robotic platform for total knee replacement procedures.
Mako RPS pairs robotic technology with the Triathlon Total Knee System and familiar workflows.
The platform uses real-time active adjustment and integrates with the Q Guidance System.
Stryker (SYK - Free Report) recently announced the U.S. commercial launch of Mako RPS (Robotic Power System), a handheld robotic platform developed for total knee replacement procedures. The system introduces Mako Handheld Robotics, extending the Mako robotics portfolio into a new segment of the orthopedic robotics market.
According to Lisa Kloes, vice president and general manager of Stryker’s Knee business, Mako RPS integrates robotic technology with the clinically proven Triathlon Total Knee System to provide surgeons with an intuitive surgical experience while preserving the familiarity of the implant and workflow they already use and trust.
Per Keith Evans, vice president and general manager of Stryker’s Mako and Enabling Technologies business, customer response during the limited market release has been exceptionally strong. Mako RPS sets a new benchmark for handheld robotic technology by combining robotic capabilities, power tool expertise and a deep understanding of surgical workflows.
Likely Trend of SYK Stock Following the News
Following the announcement, SYK shares gained 4.7% at yesterday’s close. Year to date, shares of the company have fallen 5.8% compared with the industry’s 20% decline. However, the S&P 500 has risen 10% in the same timeframe.
Stryker is likely to benefit from the commercial launch of Mako RPS, as the new platform broadens its orthopedic robotics portfolio and strengthens its leadership in robotic-assisted joint replacement. The launch could support higher adoption among surgeons while expanding the company’s reach to customers and care settings that may not have adopted robotic-assisted surgery. Compatibility with Stryker’s widely used Triathlon Total Knee System and Q Guidance System may further reinforce its integrated orthopedic ecosystem and create long-term growth opportunities.
SYK currently has a market capitalization of $121.31 billion.
Image Source: Zacks Investment Research
More on Mako RPS
The Mako RPS marks the introduction of Stryker's Mako Handheld Robotics platform while complementing the company's Mako SmartRobotics with Mako 4 multi-specialty robotic-arm-assisted platform. Mako RPS offers surgeons an intuitive handheld robotic experience that combines Stryker's expertise in robotics and power tools, broadening access to robotic-assisted orthopedic procedures.
Compatible with Stryker's clinically proven Triathlon Total Knee System, Mako RPS features intraoperative planning and a robotically enabled saw equipped with the company's patented active adjustment technology. The system responds to the surgeon's hand movements to maintain alignment with the surgical plan in real time. It eliminates the need for cutting blocks, enabling surgeons to adopt robotic technology without changing their existing workflows.
Built to integrate with Stryker’s multi-specialty Q Guidance System, Mako RPS expands the company’s ecosystem of enabling technologies across orthopedic care. The launch also builds on the strong global presence of the Mako platform, which has supported more than 2.5 million procedures across 47 countries over the past two decades, highlighting Stryker’s continued focus on advancing robotic innovation in orthopedics.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the orthopedic devices market is valued at $68.64 billion in 2026 and is expected to witness a CAGR of 4.3% through 2035.
The market is expanding, driven by the rising prevalence of orthopedic disorders, an aging population and injury incidence, integration of robotics and artificial intelligence in orthopedic surgeries and greater healthcare access and reimbursement support.
Other News
Stryker recently announced the launch of TPX HD, an advanced small bone power tool engineered to support performance, control and ergonomics across a range of complex orthopedic procedures. The tool is intended for use in total joint revisions, minimally invasive surgery and oral maxillofacial procedures.
West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
View the Zacks #1 Rank List
Image: Bigstock
Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfolio
Key Takeaways
Stryker (SYK - Free Report) recently announced the U.S. commercial launch of Mako RPS (Robotic Power System), a handheld robotic platform developed for total knee replacement procedures. The system introduces Mako Handheld Robotics, extending the Mako robotics portfolio into a new segment of the orthopedic robotics market.
According to Lisa Kloes, vice president and general manager of Stryker’s Knee business, Mako RPS integrates robotic technology with the clinically proven Triathlon Total Knee System to provide surgeons with an intuitive surgical experience while preserving the familiarity of the implant and workflow they already use and trust.
Per Keith Evans, vice president and general manager of Stryker’s Mako and Enabling Technologies business, customer response during the limited market release has been exceptionally strong. Mako RPS sets a new benchmark for handheld robotic technology by combining robotic capabilities, power tool expertise and a deep understanding of surgical workflows.
Likely Trend of SYK Stock Following the News
Following the announcement, SYK shares gained 4.7% at yesterday’s close. Year to date, shares of the company have fallen 5.8% compared with the industry’s 20% decline. However, the S&P 500 has risen 10% in the same timeframe.
Stryker is likely to benefit from the commercial launch of Mako RPS, as the new platform broadens its orthopedic robotics portfolio and strengthens its leadership in robotic-assisted joint replacement. The launch could support higher adoption among surgeons while expanding the company’s reach to customers and care settings that may not have adopted robotic-assisted surgery. Compatibility with Stryker’s widely used Triathlon Total Knee System and Q Guidance System may further reinforce its integrated orthopedic ecosystem and create long-term growth opportunities.
SYK currently has a market capitalization of $121.31 billion.
Image Source: Zacks Investment Research
More on Mako RPS
The Mako RPS marks the introduction of Stryker's Mako Handheld Robotics platform while complementing the company's Mako SmartRobotics with Mako 4 multi-specialty robotic-arm-assisted platform. Mako RPS offers surgeons an intuitive handheld robotic experience that combines Stryker's expertise in robotics and power tools, broadening access to robotic-assisted orthopedic procedures.
Compatible with Stryker's clinically proven Triathlon Total Knee System, Mako RPS features intraoperative planning and a robotically enabled saw equipped with the company's patented active adjustment technology. The system responds to the surgeon's hand movements to maintain alignment with the surgical plan in real time. It eliminates the need for cutting blocks, enabling surgeons to adopt robotic technology without changing their existing workflows.
Built to integrate with Stryker’s multi-specialty Q Guidance System, Mako RPS expands the company’s ecosystem of enabling technologies across orthopedic care. The launch also builds on the strong global presence of the Mako platform, which has supported more than 2.5 million procedures across 47 countries over the past two decades, highlighting Stryker’s continued focus on advancing robotic innovation in orthopedics.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the orthopedic devices market is valued at $68.64 billion in 2026 and is expected to witness a CAGR of 4.3% through 2035.
The market is expanding, driven by the rising prevalence of orthopedic disorders, an aging population and injury incidence, integration of robotics and artificial intelligence in orthopedic surgeries and greater healthcare access and reimbursement support.
Other News
Stryker recently announced the launch of TPX HD, an advanced small bone power tool engineered to support performance, control and ergonomics across a range of complex orthopedic procedures. The tool is intended for use in total joint revisions, minimally invasive surgery and oral maxillofacial procedures.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
SYK’s Zacks Rank & Key Picks
Stryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.